136 related articles for article (PubMed ID: 12597909)
1. Negative-strand RNA viral vectors: intravenous application of Sendai virus vectors for the systemic delivery of therapeutic genes.
Bitzer M; Ungerechts G; Bossow S; Graepler F; Sedlmeier R; Armeanu S; Bernloehr C; Spiegel M; Gross CD; Gregor M; Neubert WJ; Lauer UM
Mol Ther; 2003 Feb; 7(2):210-7. PubMed ID: 12597909
[TBL] [Abstract][Full Text] [Related]
2. Efficient propagation of single gene deleted recombinant Sendai virus vectors.
Bernloehr C; Bossow S; Ungerechts G; Armeanu S; Neubert WJ; Lauer UM; Bitzer M
Virus Res; 2004 Feb; 99(2):193-7. PubMed ID: 14749185
[TBL] [Abstract][Full Text] [Related]
3. Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
Schneider H; Mühle C; Douar AM; Waddington S; Jiang QJ; von der Mark K; Coutelle C; Rascher W
J Gene Med; 2002; 4(1):46-53. PubMed ID: 11828387
[TBL] [Abstract][Full Text] [Related]
4. Sendai virus vectors as an emerging negative-strand RNA viral vector system.
Bitzer M; Armeanu S; Lauer UM; Neubert WJ
J Gene Med; 2003 Jul; 5(7):543-53. PubMed ID: 12825193
[TBL] [Abstract][Full Text] [Related]
5. Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector.
Tsui LV; Kelly M; Zayek N; Rojas V; Ho K; Ge Y; Moskalenko M; Mondesire J; Davis J; Roey MV; Dull T; McArthur JG
Nat Biotechnol; 2002 Jan; 20(1):53-7. PubMed ID: 11753362
[TBL] [Abstract][Full Text] [Related]
6. Efficient delivery of human clotting factor IX after injection of lentiviral vectors in utero.
Chen XG; Zhu HZ; Gong JL; Li F; Xue JL
Acta Pharmacol Sin; 2004 Jun; 25(6):789-93. PubMed ID: 15169633
[TBL] [Abstract][Full Text] [Related]
7. High-level factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors.
Miao CH; Ye X; Thompson AR
Hum Gene Ther; 2003 Sep; 14(14):1297-305. PubMed ID: 14503965
[TBL] [Abstract][Full Text] [Related]
8. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo.
Miao CH; Thompson AR; Loeb K; Ye X
Mol Ther; 2001 Jun; 3(6):947-57. PubMed ID: 11407909
[TBL] [Abstract][Full Text] [Related]
9. Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells.
Wang JM; Zheng H; Sugahara Y; Tan J; Yao SN; Olson E; Kurachi K
Hum Gene Ther; 1996 Sep; 7(14):1743-56. PubMed ID: 8886845
[TBL] [Abstract][Full Text] [Related]
10. Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins.
Le Quellec S; Dane A; Enjolras N; McIntosh J; Rosales C; Negrier C; Nathwani A
Haemophilia; 2019 Jan; 25(1):e11-e18. PubMed ID: 30520547
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus vectors provide prolonged robust factor IX expression in mice.
Sclimenti CR; Neviaser AS; Baba EJ; Meuse L; Kay MA; Calos MP
Biotechnol Prog; 2003; 19(1):144-51. PubMed ID: 12573017
[TBL] [Abstract][Full Text] [Related]
12. Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo.
Riu E; Grimm D; Huang Z; Kay MA
Hum Gene Ther; 2005 May; 16(5):558-70. PubMed ID: 15916481
[TBL] [Abstract][Full Text] [Related]
13. Reduced toxicity of F-deficient Sendai virus vector in the mouse fetus.
Waddington SN; Buckley SM; Bernloehr C; Bossow S; Ungerechts G; Cook T; Gregory L; Rahim A; Themis M; Neubert WJ; Coutelle C; Lauer UM; Bitzer M
Gene Ther; 2004 Apr; 11(7):599-608. PubMed ID: 14724676
[TBL] [Abstract][Full Text] [Related]
14. Genetic modification of bone-marrow mesenchymal stem cells and hematopoietic cells with human coagulation factor IX-expressing plasmids.
Sam MR; Azadbakhsh AS; Farokhi F; Rezazadeh K; Sam S; Zomorodipour A; Haddad-Mashadrizeh A; Delirezh N; Mokarizadeh A
Biologicals; 2016 May; 44(3):170-7. PubMed ID: 26928674
[TBL] [Abstract][Full Text] [Related]
15. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques.
Nathwani AC; Davidoff AM; Hanawa H; Hu Y; Hoffer FA; Nikanorov A; Slaughter C; Ng CY; Zhou J; Lozier JN; Mandrell TD; Vanin EF; Nienhuis AW
Blood; 2002 Sep; 100(5):1662-9. PubMed ID: 12176886
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Sendai viruses expressing different levels of a foreign reporter gene.
Tokusumi T; Iida A; Hirata T; Kato A; Nagai Y; Hasegawa M
Virus Res; 2002 Jun; 86(1-2):33-8. PubMed ID: 12076827
[TBL] [Abstract][Full Text] [Related]
17. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors.
Koeberl DD; Alexander IE; Halbert CL; Russell DW; Miller AD
Proc Natl Acad Sci U S A; 1997 Feb; 94(4):1426-31. PubMed ID: 9037069
[TBL] [Abstract][Full Text] [Related]
18. Optimizing vector application for gene transfer into human hepatoblastoma cells.
Warmann SW; Armeanu S; Heitmann H; Ruck P; Seitz G; Wessels JT; Lemken ML; Lauer UM; Fuchs J; Bitzer M
Pediatr Surg Int; 2006 Sep; 22(9):733-42. PubMed ID: 16896819
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for hemophilia B with liver-specific element mediated by Rep-RBE site-specific integration system.
Xu Z; Ye J; Zhang A; Xie L; Shen Q; Xue J; Chen J
J Cardiovasc Pharmacol; 2015 Feb; 65(2):153-9. PubMed ID: 25295466
[TBL] [Abstract][Full Text] [Related]
20. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors.
Follenzi A; Sabatino G; Lombardo A; Boccaccio C; Naldini L
Hum Gene Ther; 2002 Jan; 13(2):243-60. PubMed ID: 11812281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
